Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 19 de 19
Filtrar
1.
Immunol Rev ; 274(1): 245-269, 2016 11.
Artículo en Inglés | MEDLINE | ID: mdl-27782319

RESUMEN

Innate immunity is fundamental to our defense against microorganisms. Physiologically, the intravascular innate immune system acts as a purging system that identifies and removes foreign substances leading to thromboinflammatory responses, tissue remodeling, and repair. It is also a key contributor to the adverse effects observed in many diseases and therapies involving biomaterials and therapeutic cells/organs. The intravascular innate immune system consists of the cascade systems of the blood (the complement, contact, coagulation, and fibrinolytic systems), the blood cells (polymorphonuclear cells, monocytes, platelets), and the endothelial cell lining of the vessels. Activation of the intravascular innate immune system in vivo leads to thromboinflammation that can be activated by several of the system's pathways and that initiates repair after tissue damage and leads to adverse reactions in several disorders and treatment modalities. In this review, we summarize the current knowledge in the field and discuss the obstacles that exist in order to study the cross-talk between the components of the intravascular innate immune system. These include the use of purified in vitro systems, animal models and various types of anticoagulants. In order to avoid some of these obstacles we have developed specialized human whole blood models that allow investigation of the cross-talk between the various cascade systems and the blood cells. We in particular stress that platelets are involved in these interactions and that the lectin pathway of the complement system is an emerging part of innate immunity that interacts with the contact/coagulation system. Understanding the resulting thromboinflammation will allow development of new therapeutic modalities.


Asunto(s)
Plaquetas/inmunología , Proteínas del Sistema Complemento/metabolismo , Células Endoteliales/fisiología , Inflamación/inmunología , Trombosis/inmunología , Animales , Coagulación Sanguínea , Homeostasis , Humanos , Inmunidad Innata , Calicreínas/metabolismo , Cininas/metabolismo
2.
Int J Med Microbiol ; 308(7): 969-976, 2018 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-30064820

RESUMEN

Escherichia coli-induced hemolytic uremic syndrome (eHUS) is a life-threatening complication of infection with Shiga toxin (Stx), in particular Stx2a-producing Escherichia coli. Enhanced coagulation activation with formation of microthrombi seems to be a key event in development of eHUS. Platelet activation has been postulated as a possible, but controversially debated mechanism. The present study investigated the effect of Stx2a on plasmatic coagulation and platelets. Binding studies were initially performed with ELISA and co-immunoprecipitation and supported by quartz crystal microbalance with dissipation monitoring (QCM-D). Antithrombin (AT) activity was measured using the automated BCS XP® system. ROTEM® was used for functional coagulation testing. Platelet binding and activation was studied with FACS and light-transmission aggregometry. We found binding of Stx2a to AT, an important inhibitor of blood coagulation, but only a mild albeit significant reduction of AT activity against FXa in the presence of Stx2a. QCM-D analysis also showed binding of Stx2a to heparin and an impaired binding of AT to Stx2a-bound heparin. ROTEM® using Stx2a-treated platelet-poor plasma revealed a significant, but only moderate shortening of clotting time. Neither binding nor activation of platelets by Stx2a could be demonstrated. In summary, data of this study suggest that Stx2a binds to AT, but does not induce major effects on plasmatic coagulation. In addition, no interaction with platelets occurred. The well-known non-beneficial administration of heparin in eHUS patients could be explained by the interaction of Stx2a with heparin.


Asunto(s)
Antitrombinas/metabolismo , Coagulación Sanguínea/fisiología , Heparina/metabolismo , Agregación Plaquetaria/inmunología , Toxina Shiga II/metabolismo , Plaquetas/inmunología , Síndrome Hemolítico-Urémico/microbiología , Humanos , Unión Proteica/fisiología , Escherichia coli Shiga-Toxigénica/patogenicidad
3.
Nanomedicine ; 14(3): 735-744, 2018 04.
Artículo en Inglés | MEDLINE | ID: mdl-29277639

RESUMEN

Iron-oxide nanoparticles (NPs) generated by environmental events are likely to represent health problems. α-Fe2O3 NPs were synthesized, characterized and tested in a model for toxicity utilizing human whole blood without added anticoagulant. MALDI-TOF of the corona was performed and activation markers for plasma cascade systems (complement, contact and coagulation systems), platelet consumption and release of growth factors, MPO, and chemokine/cytokines from blood cells were analyzed. The coronas formed on the pristine α-Fe2O3 NPs contained contact system proteins and they induced massive activation of the contact (kinin/kallikrein) system, as well as thrombin generation, platelet activation, and release of two pro-angiogeneic growth factors: platelet-derived growth factor and vascular endothelial growth factor, whereas complement activation was unaffected. The α-Fe2O3 NPs exhibited a noticeable toxicity, with kinin/kallikrein activation, which may be associated with hypotension and long-term angiogenesis in vivo, with implications for cancer, arteriosclerosis and pulmonary disease.


Asunto(s)
Coagulación Sanguínea , Compuestos Férricos/química , Inmunidad Innata/efectos de los fármacos , Sistema Calicreína-Quinina , Nanopartículas del Metal/administración & dosificación , Humanos , Nanopartículas del Metal/química , Factor de Crecimiento Derivado de Plaquetas/metabolismo , Corona de Proteínas/metabolismo , Factor A de Crecimiento Endotelial Vascular/metabolismo
4.
Stem Cells ; 32(9): 2430-42, 2014 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-24805247

RESUMEN

We have recently reported that therapeutic mesenchymal stromal cells (MSCs) have low engraftment and trigger the instant blood mediated inflammatory reaction (IBMIR) after systemic delivery to patients, resulting in compromised cell function. In order to optimize the product, we compared the immunomodulatory, blood regulatory, and therapeutic properties of freeze-thawed and freshly harvested cells. We found that freeze-thawed MSCs, as opposed to cells harvested from continuous cultures, have impaired immunomodulatory and blood regulatory properties. Freeze-thawed MSCs demonstrated reduced responsiveness to proinflammatory stimuli, an impaired production of anti-inflammatory mediators, increased triggering of the IBMIR, and a strong activation of the complement cascade compared to fresh cells. This resulted in twice the efficiency in lysis of thawed MSCs after 1 hour of serum exposure. We found a 50% and 80% reduction in viable cells with freshly detached as opposed to thawed in vitro cells, indicating a small benefit for fresh cells. In evaluation of clinical response, we report a trend that fresh cells, and cells of low passage, demonstrate improved clinical outcome. Patients treated with freshly harvested cells in low passage had a 100% response rate, twice the response rate of 50% observed in a comparable group of patients treated with freeze-thawed cells at higher passage. We conclude that cryobanked MSCs have reduced immunomodulatory and blood regulatory properties directly after thawing, resulting in faster complement-mediated elimination after blood exposure. These changes seem to be paired by differences in therapeutic efficacy in treatment of immune ailments after hematopoietic stem cell transplantation.


Asunto(s)
Criopreservación/métodos , Inmunoterapia/métodos , Trasplante de Células Madre Mesenquimatosas/métodos , Células Madre Mesenquimatosas/citología , Células Madre Mesenquimatosas/inmunología , Adolescente , Adulto , Anciano , Diferenciación Celular/fisiología , Proliferación Celular/fisiología , Células Cultivadas , Niño , Preescolar , Femenino , Humanos , Inmunomodulación , Inmunofenotipificación/métodos , Lactante , Masculino , Células Madre Mesenquimatosas/metabolismo , Persona de Mediana Edad , Adulto Joven
5.
Eur J Clin Invest ; 44(6): 587-96, 2014 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-24754458

RESUMEN

BACKGROUND: In several reports, C3 and C4 have been linked to diabetes and cardiovascular disease (CVD). Here, we investigate this link and the degree of C3 activation in elderly individuals. METHODS: In this study, C3 and C4 and the activation fragment C3a-desArg were analysed in 1016 subjects aged 70, in which blood pressure, lipid variables and fasting blood glucose were assessed. RESULTS: C3 levels were related to all the investigated classical cardiovascular risk factors and the metabolic syndrome (BMI, waist circumference, fat distribution, blood pressure, blood glucose levels, TG) except total cholesterol and LDL cholesterol in a highly significant fashion (Spearman up to 0,5; P < 0·0001). C4 and C3a-desArg were associated in the same fashion but less significantly, while the ratios C4/C3 or C3a-desArg/C3 were not, indicating that the association was not directly related to complement activation. The levels C3 and to a lesser degree C4 and C3a-desArg were associated particularly with CRP, but also with E-selectin and ICAM-1. In addition, C3 and C4 levels were shown to decline significantly in 15 female subjects enrolled in a weight-reduction programme over 4 months. CONCLUSION: A strong relation between C3, C4 and C3a-desArg levels, adipose tissue and risk factors of CVD was established. The data support that the adipose tissue produces complement components and generates initiators of inflammation, such as C3a and C5a, able to trigger a cyto/chemokine response, in proportion to the amount of adipose tissue. This corroborates the concept that complement contributes to the low-grade inflammation associated with obesity.


Asunto(s)
Grasa Abdominal/metabolismo , Enfermedades Cardiovasculares/etiología , Complemento C3/metabolismo , Complemento C4/metabolismo , Anciano , Biomarcadores/metabolismo , Glucemia/metabolismo , Enfermedades Cardiovasculares/metabolismo , Citocinas/metabolismo , Femenino , Humanos , Imagen por Resonancia Magnética , Masculino , Síndrome Metabólico/metabolismo , Obesidad/complicaciones , Obesidad/metabolismo , Factores de Riesgo , Relación Cintura-Cadera , Pérdida de Peso/fisiología
6.
Stem Cells ; 30(7): 1565-74, 2012 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-22522999

RESUMEN

Multipotent mesenchymal stromal cells (MSCs) are tested in numerous clinical trials. Questions have been raised concerning fate and function of these therapeutic cells after systemic infusion. We therefore asked whether culture-expanded human MSCs elicit an innate immune attack, termed instant blood-mediated inflammatory reaction (IBMIR), which has previously been shown to compromise the survival and function of systemically infused islet cells and hepatocytes. We found that MSCs expressed hemostatic regulators similar to those produced by endothelial cells but displayed higher amounts of prothrombotic tissue/stromal factors on their surface, which triggered the IBMIR after blood exposure, as characterized by formation of blood activation markers. This process was dependent on the cell dose, the choice of MSC donor, and particularly the cell-passage number. Short-term expanded MSCs triggered only weak blood responses in vitro, whereas extended culture and coculture with activated lymphocytes increased their prothrombotic properties. After systemic infusion to patients, we found increased formation of blood activation markers, but no formation of hyperfibrinolysis marker D-dimer or acute-phase reactants with the currently applied dose of 1.0-3.0 × 10(6) cells per kilogram. Culture-expanded MSCs trigger the IBMIR in vitro and in vivo. Induction of IBMIR is dose-dependent and increases after prolonged ex vivo expansion. Currently applied doses of low-passage clinical-grade MSCs elicit only minor systemic effects, but higher cell doses and particularly higher passage cells should be handled with care. This deleterious reaction can compromise the survival, engraftment, and function of these therapeutic cells.


Asunto(s)
Células Madre Mesenquimatosas/citología , Tratamiento Basado en Trasplante de Células y Tejidos , Células Endoteliales/citología , Humanos , Células Madre Mesenquimatosas/inmunología , Trombosis/sangre
7.
Adv Exp Med Biol ; 735: 257-70, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23402033

RESUMEN

Medicine today uses a wide range of biomaterials, most of which make contact with blood permanently or transiently upon implantation. Contact between blood and nonbiological materials or cells or tissue of nonhematologic origin initiates activation of the cascade systems (complement, contact activation/coagulation) of the blood, which induces platelet and leukocyte activation. Although substantial progress regarding biocompatibility has been made, many materials and medical treatment procedures are still associated with severe side effects. Therefore, there is a great need for adequate models and guidelines for evaluating the blood compatibility of biomaterials. Due to the substantial amount of cross talk between the different cascade systems and cell populations in the blood, it is advisable to use an intact system for evaluation. Here, we describe three such in vitro models for the evaluation of the biocompatibility of materials and therapeutic cells and tissues. The use of different anticoagulants and specific inhibitors in order to be able to dissect interactions between the different cascade systems and cells of the blood is discussed. In addition, we describe two clinically relevant medical treatment modalities, the integration of titanium implants and transplantation of islets of Langerhans to patients with type 1 diabetes, whose mechanisms of action we have addressed using these in vitro models.


Asunto(s)
Incompatibilidad de Grupos Sanguíneos , Proteínas del Sistema Complemento/fisiología , Prueba de Histocompatibilidad/métodos , Histocompatibilidad , Ensayo de Materiales/métodos , Animales , Anticoagulantes/farmacología , Recolección de Muestras de Sangre , Guías como Asunto , Prueba de Histocompatibilidad/instrumentación , Humanos , Inflamación/inmunología , Ensayo de Materiales/instrumentación
8.
J Immunol ; 184(5): 2686-92, 2010 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-20139276

RESUMEN

It has been reported that complement is activated on the surface of activated platelets, despite the presence of multiple regulators of complement activation. To reinvestigate the mechanisms by which activated platelets bind to complement components, the presence of complement proteins on the surfaces of nonactivated and thrombin receptor-activating peptide-activated platelets was analyzed by flow cytometry and Western blot analyses. C1q, C4, C3, and C9 were found to bind to thrombin receptor-activating peptide-activated platelets in lepirudin-anticoagulated platelet-rich plasma (PRP) and whole blood. However, inhibiting complement activation at the C1q or C3 level did not block the binding of C3 to activated platelets. Diluting PRP and chelating divalent cations also had no effect, further indicating that the deposition of complement components was independent of complement activation. Furthermore, washed, activated platelets bound added C1q and C3 to the same extent as platelets in PRP. The use of mAbs against different forms of C3 demonstrated that the bound C3 consisted of C3(H(2)O). Furthermore, exogenously added soluble complement receptor 1 was shown to bind to this form of platelet-bound C3. These observations indicate that there is no complement activation on the surface of platelets under physiological conditions. This situation is in direct contrast to a number of pathological conditions in which regulators of complement activation are lacking and thrombocytopenia and thrombotic disease are the ultimate result. However, the generation of C3(H(2)O) represents nonproteolytic activation of C3 and after factor I cleavage may act as a ligand for receptor binding.


Asunto(s)
Plaquetas/metabolismo , Complemento C3/metabolismo , Activación Plaquetaria , Receptores de Complemento 3b/metabolismo , Secuencia de Aminoácidos , Plaquetas/efectos de los fármacos , Western Blotting , Sulfatos de Condroitina/metabolismo , Activación de Complemento , Complemento C1q/metabolismo , Complemento C4/metabolismo , Complemento C9/metabolismo , Ensayo de Inmunoadsorción Enzimática , Fibrinolíticos/farmacología , Citometría de Flujo , Hirudinas/farmacología , Humanos , Oligopéptidos/farmacología , Plasma Rico en Plaquetas/efectos de los fármacos , Plasma Rico en Plaquetas/metabolismo , Unión Proteica , Proteínas Recombinantes/farmacología
9.
Adv Exp Med Biol ; 946: 185-205, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-21948369

RESUMEN

Platelet activation during thrombotic events is closely associated with complement and contact system activation, which in turn leads to inflammation. Here we review the interactions between activated platelets and the complement and contact activation systems in clotting blood. Chondroitin sulfate A (CS-A), released from alpha granules during platelet activation, is a potent mediator of crosstalk between platelets and the complement system. CS-A activates complement in the fluid phase, generating anaphylatoxins that mediate leukocyte activation. No complement activation seems to occur on the activated platelet surface, but C3 in the form of C3(H(2)O) is bound to the surfaces of activated platelets . This finding is consistent with the strong expression of membrane-bound complement regulators present at the platelet surface. CS-A exposed on the activated platelets is to a certain amount responsible for recruiting soluble regulators to the surface. Platelet-bound C3(H(2)O) acts as a ligand for leukocyte CR1 (CD35), potentially enabling platelet-leukocyte interactions. In addition, platelet activation leads to the activation of contact system enzymes, which are specifically inhibited by antithrombin, rather than by C1INH, as is the case when contact activation is induced by material surfaces. Thus, in addition to their traditional role as initiators of secondary hemostasis, platelets also act as mediators and regulators of inflammation in thrombotic events.


Asunto(s)
Plaquetas/inmunología , Proteínas del Sistema Complemento/inmunología , Inflamación/inmunología , Activación Plaquetaria/inmunología , Trombosis/inmunología , Humanos
10.
Transplantation ; 103(8): 1630-1638, 2019 08.
Artículo en Inglés | MEDLINE | ID: mdl-30896677

RESUMEN

BACKGROUND: Hepatocyte transplantation (Hctx) is a potentially attractive method for the treatment of acute liver failure and liver-based metabolic disorders. Unfortunately, the procedure is hampered by the instant blood-mediated inflammatory reaction (IBMIR), a thromboinflammatory response elicited by the vascular innate immune system, causing activation of the coagulation and complement systems and clearance of transplanted cells. Observations have also revealed platelets adhered to the surface of the hepatocytes (Hc). To establish Hctx as a clinical treatment, all factors that trigger IBMIR need to be identified and controlled. This work explores the expression of von Willebrand factor (VWF) on isolated Hc resulting in tethering of platelets. METHODS: VWF on Hc was studied by flow cytometry, confocal microscopy, immunoblot, and real-time polymerase chain reaction. Interaction between Hc and platelets was studied in a Chandler loop model. Adhesion of platelets to the hepatocyte surface was demonstrated by flow cytometry and confocal microscopy. RESULTS: Isolated Hc constitutively express VWF on their cell surface and mRNA for VWF was found in the cells. Hc and platelets, independently of coagulation formed complexes, were shown by antibody blocking studies to be dependent on hepatocyte-associated VWF and platelet-bound glycoprotein Ibα. CONCLUSIONS: VWF on isolated Hc causes, in contact with blood, adhesion of platelets, which thereby forms an ideal surface for coagulation. This phenomenon needs to be considered in hepatocyte-based reconstitution therapy and possibly even in other settings of cell transplantation.


Asunto(s)
Plaquetas/metabolismo , Regulación de la Expresión Génica , Hepatocitos/metabolismo , Trasplante de Hígado , Adhesividad Plaquetaria/fisiología , ARN/genética , Factor de von Willebrand/genética , Western Blotting , Criopreservación , Femenino , Citometría de Flujo , Hepatocitos/patología , Hepatocitos/trasplante , Humanos , Masculino , Microscopía Confocal , Unión Proteica , Factor de von Willebrand/biosíntesis
11.
Chem Commun (Camb) ; 52(5): 966-9, 2016 Jan 18.
Artículo en Inglés | MEDLINE | ID: mdl-26587574

RESUMEN

We have developed the first chondroitin sulfate polymer coated gold nanoparticles that can simultaneously overcome mulidrug resistance in cancer cells and suppress thromboinflammation triggered by the chemotherapeutic drug.

12.
Mol Immunol ; 67(1): 101-7, 2015 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-25746915

RESUMEN

Abundant reports have shown that there is a strong relationship between C3 and C3a-desArg levels, adipose tissue, and risk factors for cardiovascular disease, metabolic syndrome and diabetes. The data indicate that complement components, particularly C3, are involved in lipid metabolism. The C3 fragment, C3a-desArg, functions as a hormone that has insulin-like effects and facilitates triglyceride metabolism. Adipose tissue produces and regulates the levels of complement components, which promotes generation of inflammatory initiators such as the anaphylatoxins C3a and C5a. The anaphylatoxins trigger a cyto/chemokine response in proportion to the amount of adipose tissue present, and induce inflammation and mediate metabolic effects such as insulin resistance. These observations support the concept that complement is an important participant in lipid metabolism and in obesity, contributing to the metabolic syndrome and to the low-grade inflammation associated with obesity.


Asunto(s)
Tejido Adiposo/inmunología , Enfermedades Cardiovasculares/inmunología , Complemento C3a/inmunología , Diabetes Mellitus/inmunología , Metabolismo de los Lípidos/inmunología , Síndrome Metabólico/inmunología , Obesidad/inmunología , Tejido Adiposo/metabolismo , Tejido Adiposo/patología , Apolipoproteínas/genética , Apolipoproteínas/inmunología , Apolipoproteínas/metabolismo , Enfermedades Cardiovasculares/genética , Enfermedades Cardiovasculares/metabolismo , Enfermedades Cardiovasculares/patología , Complemento C3a/genética , Complemento C3a/metabolismo , Complemento C5a/genética , Complemento C5a/inmunología , Complemento C5a/metabolismo , Diabetes Mellitus/genética , Diabetes Mellitus/metabolismo , Diabetes Mellitus/patología , Regulación de la Expresión Génica , Humanos , Resistencia a la Insulina/inmunología , Síndrome Metabólico/genética , Síndrome Metabólico/metabolismo , Síndrome Metabólico/patología , Obesidad/genética , Obesidad/metabolismo , Obesidad/patología , Receptores de Complemento/genética , Receptores de Complemento/inmunología , Receptores de Complemento/metabolismo , Factores de Riesgo , Triglicéridos/genética , Triglicéridos/inmunología , Triglicéridos/metabolismo
13.
Thromb Haemost ; 114(6): 1207-17, 2015 Nov 25.
Artículo en Inglés | MEDLINE | ID: mdl-26293614

RESUMEN

Complement component C3 has a potential role in thrombotic pathologies. It is transformed, without proteolytic cleavage, into C3(H2O) upon binding to the surface of activated platelets. We hypothesise that C3(H2O) bound to activated platelets and to platelet-derived microparticles (PMPs) contributes to platelet-PMN complex (PPC) formation and to the binding of PMPs to PMNs. PAR-1 activation of platelets in human whole blood from normal individuals induced the formation of CD16+/CD42a+ PPC. The complement inhibitor compstatin and a C5a receptor antagonist inhibited PPC formation by 50 %, while monoclonal antibodies to C3(H2O) or anti-CD11b inhibited PPC formation by 75-100 %. Using plasma protein-depleted blood and blood from a C3-deficient patient, we corroborated the dependence on C3, obtaining similar results after reconstitution with purified C3. By analogy with platelets, PMPs isolated from human serum were found to expose C3(H2O) and bind to PMNs. This interaction was also blocked by the anti-C3(H2O) and anti-CD11b monoclonal antibodies, indicating that C3(H2O) and CD11b are involved in tethering PMPs to PMNs. We confirmed the direct interaction between C3(H2O) and CD11b by quartz crystal microbalance analysis using purified native C3 and recombinant CD11b/CD18 and by flow cytometry using PMP and recombinant CD11b. Transfectants expressing CD11b/CD18 were also shown to specifically adhere to surface-bound C3(H2O). We have identified contact-activated C3(H2O) as a novel ligand for CD11b/CD18 that mediates PPC formation and the binding of PMPs to PMNs. Given the various roles of C3 in thrombotic reactions, this finding is likely to have important pathophysiological implications.


Asunto(s)
Plaquetas/metabolismo , Antígeno CD11b/metabolismo , Antígenos CD18/metabolismo , Micropartículas Derivadas de Células/metabolismo , Activación de Complemento , Complemento C3/metabolismo , Neutrófilos/metabolismo , Animales , Anticuerpos Monoclonales/inmunología , Anticuerpos Monoclonales/farmacología , Antígeno CD11b/inmunología , Antígenos CD18/inmunología , Células CHO , Cricetinae , Cricetulus , Humanos , Fragmentos de Péptidos/farmacología , Péptidos Cíclicos/farmacología , Unión Proteica , Mapeo de Interacción de Proteínas , Receptor de Anafilatoxina C5a/antagonistas & inhibidores , Receptor PAR-1/agonistas , Receptor PAR-1/metabolismo , Proteínas Recombinantes/metabolismo , Transfección
14.
Mol Immunol ; 67(1): 108-18, 2015 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-25886718

RESUMEN

In recent years, the view of platelets has changed from mere elements of hemostasis to immunological multitaskers. They are connected in manifold ways to other cellular and humoral components of the immune network, one of which is the complement system, a potent player in soluble innate immunity. Our article reviews the crucial and complex interplay between platelets and complement, focusing on mutual regulation of these two interaction partners by their respective molecular mechanisms. Furthermore, the putative relevance of these processes to infectious diseases, inflammatory conditions, and autoimmune disorders, as well as the treatment of patients with biomaterials is highlighted.


Asunto(s)
Enfermedades Autoinmunes/inmunología , Infecciones Bacterianas/inmunología , Plaquetas/inmunología , Proteínas del Sistema Complemento/inmunología , Micosis/inmunología , Virosis/inmunología , Enfermedades Autoinmunes/genética , Enfermedades Autoinmunes/patología , Infecciones Bacterianas/genética , Infecciones Bacterianas/microbiología , Infecciones Bacterianas/patología , Plaquetas/patología , Activación de Complemento , Proteínas Inactivadoras del Complemento C3b/genética , Proteínas Inactivadoras del Complemento C3b/inmunología , Proteínas del Sistema Complemento/genética , Regulación de la Expresión Génica , Humanos , Inmunidad Innata , Micosis/genética , Micosis/microbiología , Micosis/patología , Receptores de Complemento/genética , Receptores de Complemento/inmunología , Transducción de Señal , Virosis/genética , Virosis/patología , Virosis/virología
15.
Biomaterials ; 36: 55-65, 2015 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-25292422

RESUMEN

Inappropriate complement activation is often responsible for incompatibility reactions that occur when biomaterials are used. Complement activation is therefore a criterion included in legislation regarding biomaterials testing. However, no consensus is yet available regarding appropriate complement-activation-related test parameters. We examined protein adsorption in plasma and complement activation/cytokine release in whole blood incubated with well-characterized polymers. Strong correlations were found between the ratio of C4 to its inhibitor C4BP and generation of 10 (mainly pro-inflammatory) cytokines, including IL-17, IFN-γ, and IL-6. The levels of complement activation products correlated weakly (C3a) or not at all (C5a, sC5b-9), confirming their poor predictive values. We have demonstrated a direct correlation between downstream biological effects and the proteins initially adhering to an artificial surface after contact with blood. Consequently, we propose the C4/C4BP ratio as a robust, predictor of biocompatibility with superior specificity and sensitivity over the current gold standard.


Asunto(s)
Materiales Biocompatibles/efectos adversos , Activación de Complemento/efectos de los fármacos , Inflamación/sangre , Inflamación/inducido químicamente , Polímeros/efectos adversos , Proteína de Unión al Complemento C4b/inmunología , Complejo de Ataque a Membrana del Sistema Complemento/inmunología , Proteínas del Sistema Complemento/inmunología , Humanos , Inflamación/inmunología , Interferón gamma/inmunología , Interleucina-17/sangre , Interleucina-17/inmunología , Interleucina-6/sangre , Interleucina-6/inmunología
16.
Biomaterials ; 35(11): 3688-96, 2014 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-24462362

RESUMEN

Liposomes are becoming increasingly important as drug delivery systems, to target a drug to specific cells and tissues and thereby protecting the recipient from toxic effects of the contained drug. Liposome preparations have been described to activate complement. In this study, we have investigated complement activation triggered by neutral dimyristoyl-phosphocholine (DMPC) liposomes in human plasma and whole-blood systems. Incubation in plasma led to the generation of complement activation products (C3a and sC5b-9). Unexpectedly, investigations of surface-bound C3 revealed contact activated, conformationally changed C3 molecules on the liposomes. These changes were characterized by Western blotting with C3 monoclonal antibodies, and by incubating liposomes with purified native C3 and factors I and H. Quartz crystal microbalance analysis confirmed binding of C3 to planar DMPC surfaces. In addition, we demonstrated that DMPC liposomes bound to or were phagocytized by granulocytes in a complement-dependent manner, as evidenced by the use of complement inhibitors. In summary, we have shown that C3 is activated both by convertase-dependent cleavage, preferentially in the fluid phase, by mechanisms which are not well elucidated, and also by contact activation into C3(H2O) on the DMPC surface. In particular, this contact activation has implications for the therapeutic regulation of complement activation during liposome treatment.


Asunto(s)
Activación de Complemento/efectos de los fármacos , Complemento C3/metabolismo , Liposomas/metabolismo , Fosfolípidos/farmacología , Adsorción , Sistemas de Computación , Dimiristoilfosfatidilcolina/farmacología , Electroforesis en Gel de Poliacrilamida , Citometría de Flujo , Humanos , Modelos Biológicos , Fagocitosis/efectos de los fármacos , Unión Proteica/efectos de los fármacos , Proteolisis/efectos de los fármacos , Tecnicas de Microbalanza del Cristal de Cuarzo
17.
PLoS One ; 9(1): e85040, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24454787

RESUMEN

Investigation into predictors for treatment outcome is essential to improve the clinical efficacy of therapeutic multipotent mesenchymal stromal cells (MSCs). We therefore studied the possible harmful impact of immunogenic ABO blood groups antigens - genetically governed antigenic determinants - at all given steps of MSC-therapy, from cell isolation and preparation for clinical use, to final recipient outcome. We found that clinical MSCs do not inherently express or upregulate ABO blood group antigens after inflammatory challenge or in vitro differentiation. Although antigen adsorption from standard culture supplements was minimal, MSCs adsorbed small quantities of ABO antigen from fresh human AB plasma (ABP), dependent on antigen concentration and adsorption time. Compared to cells washed in non-immunogenic human serum albumin (HSA), MSCs washed with ABP elicited stronger blood responses after exposure to blood from healthy O donors in vitro, containing high titers of ABO antibodies. Clinical evaluation of hematopoietic stem cell transplant (HSCT) recipients found only very low titers of anti-A/B agglutination in these strongly immunocompromised patients at the time of MSC treatment. Patient analysis revealed a trend for lower clinical response in blood group O recipients treated with ABP-exposed MSC products, but not with HSA-exposed products. We conclude, that clinical grade MSCs are ABO-neutral, but the ABP used for washing and infusion of MSCs can contaminate the cells with immunogenic ABO substance and should therefore be substituted by non-immunogenic HSA, particularly when cells are given to immunocompentent individuals.


Asunto(s)
Sistema del Grupo Sanguíneo ABO/inmunología , Trasplante de Células Madre Mesenquimatosas , Células Madre Mesenquimatosas/citología , Sistema del Grupo Sanguíneo ABO/sangre , Sistema del Grupo Sanguíneo ABO/genética , Adolescente , Adsorción , Adulto , Anciano , Anticuerpos/inmunología , Células Cultivadas , Niño , Metilación de ADN/genética , Genotipo , Humanos , Persona de Mediana Edad , Regiones Promotoras Genéticas/genética , ARN Mensajero/genética , ARN Mensajero/metabolismo , Resultado del Tratamiento , Regulación hacia Arriba
18.
PLoS One ; 5(9): e12889, 2010 Sep 23.
Artículo en Inglés | MEDLINE | ID: mdl-20886107

RESUMEN

BACKGROUND: Exposure of chondroitin sulfate A (CS-A) on the surface of activated platelets is well established. The aim of the present study was to investigate to what extent CS-A contributes to the binding of the complement recognition molecule C1q and the complement regulators C1 inhibitor (C1INH), C4b-binding protein (C4BP), and factor H to platelets. PRINCIPAL FINDINGS: Human blood serum was passed over Sepharose conjugated with CS-A, and CS-A-specific binding proteins were identified by Western blotting and mass spectrometric analysis. C1q was shown to be the main protein that specifically bound to CS-A, but C4BP and factor H were also shown to interact. Binding of C1INH was dependent of the presence of C1q and then not bound to CS-A from C1q-depleted serum. The specific interactions observed of these proteins with CS-A were subsequently confirmed by surface plasmon resonance analysis using purified proteins. Importantly, C1q, C4BP, and factor H were also shown to bind to activated platelets and this interaction was inhibited by a CS-A-specific monoclonal antibody, thereby linking the binding of C1q, C4BP, and factor H to exposure of CS-A on activated platelets. CS-A-bound C1q was also shown to amplify the binding of model immune complexes to both microtiter plate-bound CS-A and to activated platelets. CONCLUSIONS: This study supports the concept that CS-A contributes to the binding of C1q, C4BP, and factor H to platelets, thereby adding CS-A to the previously reported binding sites for these proteins on the platelet surface. CS-A-bound C1q also seems to amplify the binding of immune complexes to activated platelets, suggesting a role for this molecule in immune complex diseases.


Asunto(s)
Plaquetas/metabolismo , Sulfatos de Condroitina/farmacología , Proteínas del Sistema Complemento/metabolismo , Activación Plaquetaria/efectos de los fármacos , Plaquetas/efectos de los fármacos , Proteínas Inactivadoras del Complemento 1/metabolismo , Proteína Inhibidora del Complemento C1 , Complemento C1q/metabolismo , Proteína de Unión al Complemento C4b/metabolismo , Factor H de Complemento/metabolismo , Humanos , Unión Proteica/efectos de los fármacos
19.
Prostate ; 67(4): 378-88, 2007 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-17219380

RESUMEN

BACKGROUND: Prostasomes are secretory granules produced by the glandular epithelial cells of the prostate. Seminal prostasomes contain high amounts of Tissue Factor (TF) but no studies of TF on malignant cell prostasomes have been made. Here we compare the expression, phosphorylation, and function of TF on prostasomes of different origin. METHODS: TF was detected on prostasomes isolated from seminal fluid and human prostate cancer cell lines (PC-3, DU145, and LNCaP) using FACS and enzyme immunoassay (EIA). Incubation of prostasomes with radioactive ATP under conditions favoring protein kinase A activity led to phosphorylation of TF as detected by immunoprecipitation and SDS-PAGE. The prothrombotic effect of prostasomes was investigated in whole blood and recalcified plasma. Blocking experiments were performed using anti-TF antibodies and corn trypsin inhibitor. RESULTS: TF was expressed on all tested prostasome preparations with lowest values found for seminal ones. Prostasomal TF was the main endogenous substrate for prostasomal protein kinase A. All tested prostasome preparations greatly enhanced the rate of clot formation in a dose-dependent fashion, that is, the clotting capability of prostasomes seemed to be related to the extent of their expression of TF. In addition, the density of the clot varied between different prostasome preparations. When incubated in whole blood, prostasomes were found to associate to WBC thereby inducing them to express and release TF. CONCLUSIONS: These data show that TF is overexpressed and also subjected to phosphorylation by malignant cell prostasomes. This suggests major roles for prostasomes in thrombotic events that occur in some advanced cases of prostate cancer.


Asunto(s)
Neoplasias de la Próstata/metabolismo , Neoplasias de la Próstata/secundario , Vesículas Secretoras/patología , Trombosis/etiología , Trombosis/patología , Calcio/sangre , Línea Celular Tumoral , Citometría de Flujo , Humanos , Técnicas para Inmunoenzimas , Masculino , Nefelometría y Turbidimetría , Fosforilación , Próstata/metabolismo , Próstata/patología , Proteínas Quinasas/metabolismo , Vesículas Secretoras/metabolismo , Epitelio Seminífero/metabolismo , Epitelio Seminífero/patología , Tromboplastina/metabolismo , Trombosis/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA